Sun Pharma may get windfall gains on cancer drug Doxil

The company began supplying Doxil on Special FDA importation last year owing to shortages in the US and finally received approval in Feb 2013 becoming the only other player besides the innovator in the space.
  • Language
  • App
  • Subscriptions
  • Specials
  • Sign-In
  • Register
GeStepAhead Masteryourmoney Earnings
moneycontrol.com

Home » News » Business

Sep 26, 2013, 03.55 PM | Source: CNBC-TV18

Sun Pharma may get windfall gains on cancer drug Doxil

The company began supplying Doxil on Special FDA importation last year owing to shortages in the US and finally received approval in Feb 2013 becoming the only other player besides the innovator in the space.

Like this story, share it with millions of investors on M3

Sun Pharma may get windfall gains on cancer drug Doxil

The company began supplying Doxil on Special FDA importation last year owing to shortages in the US and finally received approval in Feb 2013 becoming the only other player besides the innovator in the space.

Post Your Comments

Share Cancel

Ekta Batra (more)

Markets Anchor & Financial Analyst, CNBC-TV18 |

One loss might be another one’s gain and that is applicable for Sun Pharma today. The stock is up on news that the company might reap windfall gains on one of its US drugs Doxil generic used for cancer.

Reason being, Johnson and Johnson the innovator of Doxil is facing  supply disruptions due to production issues at Ben Venue, its manufacturing partner. This means Sun Pharma will become the sole supplier in the US benefiting till J&J supplies resume (which the company said they have no current visibility on).

Also Read: Sun Pharmaceuticals files ANDAs for 4 products in Q1FY14

Analysts are optimistic on this opportunity and are of the opinion that Sun could repeat last year’s success with Doxil generic this year for example, JPM expects further gains to the US business that is estimated to grow an already robust 25% in FY14 to USD 1.4 billion (Sun sold USD 120 million worth of Doxil in CY12 and USD 63 million YTD in CY13).

On a side note, this drug seems to be lucky for Sun Pharma. The company began supplying the drug on Special FDA importation last year owing to shortages in the US and finally received approval in Feb 2013 becoming the only other player besides the innovator in the space.

Ads by Google

Buy, Hold, Sell ? Hear it first on M3
Sun Pharma may get windfall gains on cancer drug Doxil

See all

Get started using your favorite social network

or

Login using moneycontrol ID

Username
Password

Need help logging in? Reset password.

Don´t have an account? Sign Up

Get started using your favorite social network

or

Simply sign up using this short form

* mandatory

UserName*

Username should be atleast 4 character

Password*

Password should be 8 or more characters,
atleast 1 number, 1 symbol & 1 upper case letter

Alert

Your Password should contain
  • 8 or more characters
  • At least 1 number
  • At least 1 symbol
  • At least 1 upper case letter
Confirm Password*
Email
Already have an account? Login